Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk

Janka Mátrai(Vlaams Instituut voor Biotechnologie), Alessio Cantore(Vita-Salute San Raffaele University), Cynthia C. Bartholomae(National Center for Tumor Diseases), Andrea Annoni(The San Raffaele Telethon Institute for Gene Therapy), Wei Wang(National Center for Tumor Diseases), Abel Acosta‐Sanchez(Vlaams Instituut voor Biotechnologie), Ermira Samara-Kuko(Vlaams Instituut voor Biotechnologie), Liesbeth De Waele(Vlaams Instituut voor Biotechnologie), Ling Ma(Vlaams Instituut voor Biotechnologie), Pietro Genovese(Vita-Salute San Raffaele University), Martina Damo(Vita-Salute San Raffaele University), Anne I.J. Arens(National Center for Tumor Diseases), Kevin Goudy(The San Raffaele Telethon Institute for Gene Therapy), Timothy C. Nichols(University of North Carolina at Chapel Hill), Christof von Kalle(National Center for Tumor Diseases), Marinee Chuah(Vlaams Instituut voor Biotechnologie), Maria Grazia Roncarolo(Vita-Salute San Raffaele University), Manfred Schmidt(GTx (United States)), Thierry VandenDriessche(Vlaams Instituut voor Biotechnologie), Luigi Naldini(Vita-Salute San Raffaele University)
Hepatology
February 18, 2011
Cited by 136Open Access
Full Text

Abstract

UNLABELLED: Lentiviral vectors are attractive tools for liver-directed gene therapy because of their capacity for stable gene expression and the lack of preexisting immunity in most human subjects. However, the use of integrating vectors may raise some concerns about the potential risk of insertional mutagenesis. Here we investigated liver gene transfer by integrase-defective lentiviral vectors (IDLVs) containing an inactivating mutation in the integrase (D64V). Hepatocyte-targeted expression using IDLVs resulted in the sustained and robust induction of immune tolerance to both intracellular and secreted proteins, despite the reduced transgene expression levels in comparison with their integrase-competent vector counterparts. IDLV-mediated and hepatocyte-targeted coagulation factor IX (FIX) expression prevented the induction of neutralizing antibodies to FIX even after antigen rechallenge in hemophilia B mice and accounted for relatively prolonged therapeutic FIX expression levels. Upon the delivery of intracellular model antigens, hepatocyte-targeted IDLVs induced transgene-specific regulatory T cells that contributed to the observed immune tolerance. Deep sequencing of IDLV-transduced livers showed only rare genomic integrations that had no preference for gene coding regions and occurred mostly by a mechanism inconsistent with residual integrase activity. CONCLUSION: IDLVs provide an attractive platform for the tolerogenic expression of intracellular or secreted proteins in the liver with a substantially reduced risk of insertional mutagenesis.


Related Papers

No related papers found

Powered by citation graph analysis